Immatics

Immatics is a biotechnology company focused on developing targeted immunotherapies for cancer patients, particularly in treating solid tumors. The company combines the discovery of cancer immunotherapy targets with the development of specific T cell receptors to enable a robust immune response. Immatics' pipeline includes Adoptive Cell Therapies and TCR Bispecifics, and it collaborates with global leaders in the pharmaceutical industry. The company's mission is to advance its therapies to improve the lives of cancer patients, and it maintains a strong commitment to innovation in immunotherapy technologies.